2023
Racial and Socioeconomic Disparities in Long-Term Outcomes in ≥1 Year Allogeneic Hematopoietic Cell Transplantation Survivors: A CIBMTR Analysis
Blue B, Brazauskas R, Chen K, Patel J, Zeidan A, Steinberg A, Ballen K, Kwok J, Rotz S, Perez M, Kelkar A, Ganguly S, Wingard J, Lad D, Sharma A, Badawy S, Lazarus H, Hashem H, Szwajcer D, Knight J, Bhatt N, Page K, Beattie S, Arai Y, Liu H, Arnold S, Freytes C, Abid M, Beitinjaneh A, Farhadfar N, Wirk B, Winestone L, Agrawal V, Preussler J, Seo S, Hashmi S, Lehmann L, Wood W, Rangarajan H, Saber W, Majhail N. Racial and Socioeconomic Disparities in Long-Term Outcomes in ≥1 Year Allogeneic Hematopoietic Cell Transplantation Survivors: A CIBMTR Analysis. Transplantation And Cellular Therapy 2023, 29: 709.e1-709.e11. PMID: 37482244, PMCID: PMC11258715, DOI: 10.1016/j.jtct.2023.07.013.Peer-Reviewed Original ResearchConceptsHematopoietic cell transplantationLong-term outcomesAllogeneic hematopoietic cell transplantationRace/ethnicityNonrelapse mortalityOverall survivalNon-Hispanic blacksNon-Hispanic whitesSocioeconomic statusMyeloid leukemiaNeighborhood poverty levelFirst allogeneic hematopoietic cell transplantationZip codesAdult allogeneic HCT recipientsMarrow Transplant Research databaseHematopoietic cell transplantation (HCT) survivorsAllogeneic hematopoietic cell transplantation survivorsAllogeneic HCT survivorsAllogeneic HCT recipientsHigh-poverty areasLong-term survivorsStandardized mortality ratioAcute lymphocytic leukemiaAcute myeloid leukemiaChronic myeloid leukemiaAn overview of novel therapies in advanced clinical testing for acute myeloid leukemia
Venugopal S, Xie Z, Zeidan A. An overview of novel therapies in advanced clinical testing for acute myeloid leukemia. Expert Review Of Hematology 2023, 16: 109-119. PMID: 36718500, DOI: 10.1080/17474086.2023.2174521.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsBridged Bicyclo Compounds, HeterocyclicHumansLeukemia, Myeloid, AcuteMutationRecurrenceConceptsAML therapyMolecular pathogenesisApproval of midostaurinPathophysiology of AMLMeasurable residual diseaseAdvanced clinical testingClinical trial developmentAcute myeloid leukemiaCell surface antigensDevelopment of agentsDisease relapseImmune environmentAML treatmentResidual diseaseTherapeutic armamentariumMyeloid leukemiaNovel therapiesSurface antigenClinical testingTrial developmentTherapyAMLEscape mechanismsGene mutationsRelapse
2022
In vivo anti-tumor effect of PARP inhibition in IDH1/2 mutant MDS/AML resistant to targeted inhibitors of mutant IDH1/2
Gbyli R, Song Y, Liu W, Gao Y, Biancon G, Chandhok NS, Wang X, Fu X, Patel A, Sundaram R, Tebaldi T, Mamillapalli P, Zeidan AM, Flavell RA, Prebet T, Bindra RS, Halene S. In vivo anti-tumor effect of PARP inhibition in IDH1/2 mutant MDS/AML resistant to targeted inhibitors of mutant IDH1/2. Leukemia 2022, 36: 1313-1323. PMID: 35273342, PMCID: PMC9103411, DOI: 10.1038/s41375-022-01536-x.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaMyelodysplastic syndromeMDS/acute myeloid leukemiaRefractory acute myeloid leukemiaPARP inhibitionVivo anti-tumor effectsAlternate therapeutic optionsSubset of AMLAnti-tumor effectsPre-clinical studiesRibose polymerase inhibitorsSerial transplantation assaysHomologous recombination defectsTherapeutic optionsTreatment optionsOverall engraftmentHigh relapseIDH inhibitionMyeloid leukemiaIsocitrate dehydrogenase 1Small molecule inhibitorsCell frequencyXeno-graftsIDH1/2 mutationsMalignant transformation
2014
Beyond hypomethylating agents failure in patients with myelodysplastic syndromes
Zeidan AM, Kharfan-Dabaja MA, Komrokji RS. Beyond hypomethylating agents failure in patients with myelodysplastic syndromes. Current Opinion In Hematology 2014, 21: 123-130. PMID: 24335709, PMCID: PMC4124617, DOI: 10.1097/moh.0000000000000016.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsAzacitidineDNA MethylationHematopoietic Stem Cell TransplantationHumansInduction ChemotherapyLenalidomideMolecular Targeted TherapyMyelodysplastic SyndromesPrognosisRecurrenceRetreatmentThalidomideTransplantation, HomologousTreatment FailureTreatment OutcomeConceptsMyelodysplastic syndromeAllogeneic stem cell transplantationPathogenesis of MDSOnly curative modalityStem cell transplantationCombination treatment strategiesCombination therapeutic strategiesNovel therapeutic approachesHMA failureHMA therapyCurative modalityObjective responseRelapse rateDismal prognosisProlong survivalInvestigational agentsModest efficacyCell transplantationClinical trialsTreatment strategiesTherapeutic approachesTherapeutic strategiesBiologic underpinningsMost respondersMolecular pathways
2013
HLA-Haploidentical Donor Lymphocyte Infusions for Patients with Relapsed Hematologic Malignancies after Related HLA-Haploidentical Bone Marrow Transplantation
Zeidan AM, Forde PM, Symons H, Chen A, Smith BD, Pratz K, Carraway H, Gladstone DE, Fuchs EJ, Luznik L, Jones RJ, Bolaños-Meade J. HLA-Haploidentical Donor Lymphocyte Infusions for Patients with Relapsed Hematologic Malignancies after Related HLA-Haploidentical Bone Marrow Transplantation. Transplantation And Cellular Therapy 2013, 20: 314-318. PMID: 24296490, PMCID: PMC4010132, DOI: 10.1016/j.bbmt.2013.11.020.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAntineoplastic Agents, AlkylatingBone Marrow TransplantationChildChild, PreschoolCyclophosphamideFemaleGraft vs Host DiseaseHaplotypesHLA AntigensHumansLeukemia, Myeloid, AcuteLymphocyte TransfusionLymphomaMaleMiddle AgedRecurrenceRemission InductionSurvival AnalysisT-LymphocytesTransplantation ConditioningTransplantation, IsogeneicConceptsPost-transplantation cyclophosphamideDonor lymphocyte infusionBone marrow transplantationComplete responseLymphocyte infusionMarrow transplantationT-cell-replete bone marrow transplantationHLA-haploidentical bone marrow transplantationRelapsed hematologic malignanciesTreatment of relapseCells/Acute myeloid leukemiaAcute GVHDChronic GVHDAcceptable toxicityHost diseaseDurable responsesMedian durationMedian ageNonmyeloablative conditioningMedian timeEntire cohortHematologic malignanciesMyeloid leukemiaGrade 3